Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Formula | C32H37N5O3 |
|||
Molecular Weight | 539.67 | CAS No. | 1396772-26-1 | |
Solubility (25°C)* | In vitro | DMSO | 2 mg/mL (3.7 mM) | |
Water | Insoluble | |||
Ethanol | Insoluble | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
Description | EPZ005687 is a potent and selective inhibitor of EZH2 with Ki of 24 nM in a cell-free assay, 50-fold selectivity against EZH1 and 500-fold selectivity against 15 other protein methyltransferases. | ||
---|---|---|---|
Targets |
|
||
In vitro | EPZ005687 shows concentration-dependent inhibition of PRC2 enzymatic activity with an IC50 value of 54 nM. It is a direct inhibitor of PRC2 enzymatic activity and does not function by disrupting the protein-protein interactions among the PRC2 subunits. EPZ005687 binds in the SAM pocket of the EZH2 SET domain and is a SAM-competitive inhibitor of EZH2 enzyme activity. The affinity of EPZ005687 is similar (within a two-fold range) for PRC2 complexes containing wild-type and Tyr641 mutant EZH2, but significantly greater affinity for the A677G mutant enzyme (5.4-fold). EPZ005687 reduces H3K27 methylation in various lymphoma cells. It shows robust cell killing in heterozygous Tyr641 or Ala677 mutant cells, with minimal effects on the proliferation of wild-type cells. EPZ005687 increases G1 phase of the cell cycle with correlative decreases in the S as well as the G2/M phases. In a Tyr641 mutant lymphoma cell line, EPZ005687 can lead to derepression of known EZH2 target genes and affect genes specifically repressed by the EZH2 Tyr641 mutant. [1] |
||
In vivo | EPZ005687, a selective inhibitor of methyltransferase EZH2, significantly inhibits the development of TAC-induced PAH in an EZH2-SOD1-ROS dependent manner. |
Kinase Assay: |
|
---|---|
Cell Assay: |
|
Animal Study: |
|
|
, , Oncogene, 2015, 34(48):5869-78.
, , J Biol Chem, 2017, 292(18):7578-7587
Data from [Data independently produced by , , Nature, 2018, 560(7718):372-376]
EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A [ J Exp Clin Cancer Res, 2023, 42(1):320] | PubMed: 38008711 |
Role of EZH2-mediated H3K27me3 in placental ADAM12-S expression: implications for fetoplacental growth [ BMC Med, 2022, 20(1):189] | PubMed: 35610640 |
Remarkable Synergy When Combining EZH2 Inhibitors with YM155 Is H3K27me3-Independent [ Cancers (Basel), 2022, 15(1)208] | PubMed: 36612203 |
H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model [ Cancer Cell, 2021, 39(3):407-422.e13] | PubMed: 33545065 |
Targeting EZH2-mediated methylation of histone 3 inhibits proliferation of pediatric acute monocytic leukemia cells in vitro [ Cancer Biol Ther, 2021, 22(4):333-344] | PubMed: 33978549 |
Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infection. [ Nat Commun, 2020, 11(1):604] | PubMed: 32001678 |
EZH2-mediated Epigenetic Silencing of miR-29/miR-30 targets LOXL4 and contributes to Tumorigenesis, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer [ Theranostics, 2020, 10(19):8494-8512] | PubMed: 32754259 |
Selective Sensitivity of EZH2 Inhibitors Based on Synthetic Lethality in ARID1A-deficient Gastric Cancer [ Gastric Cancer, 2020, 10.1007/s10120-020-01094-0] | PubMed: 32506298 |
Systematic Analysis of Drug Vulnerabilities Conferred by Tumor Suppressor Loss. [ Cell Rep, 2019, 27(11):3331-3344] | PubMed: 31189115 |
The Attenuation of Trophoblast Invasion Caused by the Downregulation of EZH2 Is Involved in the Pathogenesis of Human Recurrent Miscarriage [ Mol Ther Nucleic Acids, 2019, 14:377-387] | PubMed: 30710891 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.